There was an empty chair in the team photograph. Tim Funnell thought it required an explanation. Monograph Capital was recruiting, and he had shared the announcement with his network. Anyone examining the picture too closely might, he suggested, mistake the vacancy for a change in management. The explanation was less dramatic: he had got up to take the photograph. His latest promotion was to “team photographer”.
It is a small joke with an unusually good fit. Funnell’s working life involves moving around the table: investor, founder, operations executive, interim chief executive, director. In one company he helps supply the capital. In another he helps get the business running. Sometimes the useful contribution is to occupy the chair; sometimes it is to make room for someone else.
Ascend Advanced Therapies offers a particularly clear example. Funnell was its founding CEO. When the business emerged publicly in March 2023 with more than $130 million raised, manufacturing executive Mike Stella took over. Funnell remains on the board. A founder’s biography can make every appointment sound permanent. His contains a handover worth lingering over.
Before there was a company
The route began with science. Funnell took his undergraduate degree at Cambridge and completed a DPhil at Oxford, where he trained in pharmacology. Then came Boston Consulting Group in London, followed by company building and investment work at Syncona, Third Rock Ventures and Oxford Sciences. Those moves put him among researchers, financiers and operating teams on both sides of the Atlantic.
His early company connections included Autolus, Gyroscope and Casma. The repeated word in those roles is founding. It places him near the stage when a business still needs to acquire its shape: who will join, how it will be financed, which responsibilities belong to whom. The company name may already exist. Much of the company still has to be made.
At MiroBio, that distinction became a job description. Funnell was an entrepreneur in residence at Oxford Science Enterprises when the business was being assembled. He moved into its day-to-day operations, becoming vice president of operations and a co-founder. MiroBio launched in 2019 around research from Oxford professors Simon Davis and Richard Cornall.
The founding connections crossed an ocean. Cornall knew Srini Akkaraju from Stanford. Akkaraju, founder of Samsara BioCapital, introduced Eliot Charles, who became launch CEO and later chair. Oxford’s investment and commercialisation teams helped bring the company together. Funnell’s contribution sat inside that collection of relationships, turning a proposed enterprise into a place where people could work.
That early home was Oxford’s BioEscalator. MiroBio subsequently moved to Oxford Science Park as it grew. Looking back in the BioEscalator’s 2025 portfolio introduction, Funnell recalled the practical help and community of the first location, and the affection the founding team retained for its time there. The address had become part of the company’s memory.
An exit, with the arithmetic attached
In August 2022, Gilead announced an agreement to acquire MiroBio for approximately $405 million in cash, subject to adjustments. The transaction closed the following month. Gilead’s quarterly filing recorded the completed purchase at $414 million. The two numbers describe different stages of the same transaction, a useful detail when a company’s history gets compressed into a headline.
For the people building MiroBio, the interval from its 2019 launch to the agreement was three years. The research behind it had taken much longer. A quick corporate timetable can sit on top of a long academic one. Funnell’s part belonged to the stretch in which work developed within a university became an independent organisation, complete with colleagues, premises and investors.
In a 2023 investment discussion, Funnell offered a plain account of why capital would eventually move again after a hesitant period. Venture funds still held money, he said, and their investors paid them fees to put it to work. The observation brought the discussion back to the obligations of the fund itself. Fundraising creates another assignment: finding businesses in which that capital can be deployed.
By then he had also helped establish Monograph Capital. Founded in 2021, the firm brought together Funnell, Fred Cohen and Charles Conn. Its team spans London and San Francisco, giving institutional form to the transatlantic connections already running through his career. Scientific training and commercial experience sit beside one another in the partnership.
The portfolio matters, but so does the way the partners participate. Funnell’s operating roles make an investment relationship unusually tangible. A board appointment is one sort of involvement. Taking responsibility inside a new business gives an investor another view of what the money must accomplish. MiroBio supplied that experience before Monograph became his principal professional home.
Build it. Then pass the keys.
At Ascend, the opportunity concerned facilities and teams that already existed. Companies had built internal manufacturing capabilities for their own programmes. Maintaining and fully using those operations could become difficult. Funnell described a model that would separate those capabilities into a service business, serving both the original owner and additional customers.
The proposition was organisational as much as financial. Expertise accumulated inside one company could become useful to several. Buying equipment alone would tell only part of that story; the experienced people and their working methods were central to the offer. Ascend’s launch brought together teams across the United Kingdom, Germany and the United States.
Monograph helped create the business, with Cohen as chair, Funnell as interim CEO and Freddie Dear leading corporate development. By the public launch, Ascend reported approximately 120 staff and total funding of $132.5 million. Those figures describe the assembled company at that point, rather than a promise about how large it might eventually become.
The CEO handover gave that assembly a next stage. Stella brought a manufacturing background, including a previous chief operating officer role at Cognate Bioservices. Funnell publicly welcomed the appointment of his successor. Today Ascend lists him as a director representing Monograph. The founding assignment had changed; the relationship continued.
March 2023: an existing team, assembled into a new business.
The buildings count, too
In January 2023, Funnell joined the advisory board of Mission Street, a developer working on research and innovation buildings. Its pipeline then exceeded one million square feet across Oxford, Cambridge and Bristol. The appointment extended his attention to another part of company formation: the physical setting in which a young organisation tries to grow.
His stated interest was specific. Laboratories should be thoughtfully designed and properly executed. Proximity to other research organisations mattered, as did the ability of buildings to encourage collaboration and an enjoyable working environment. For someone who had helped choose MiroBio’s first premises, these were questions with a practical history.
Property can look like scenery in a founder’s story. It becomes the plot when a team needs a suitable place to work. Mission Street wanted advice from people who understood companies at different stages of development. Funnell brought experience of moving from the investor’s view of a business to its daily operating requirements.
“thoughtfully designed and well executed”Tim Funnell, on laboratory space, 2023
A network you can belong to
Another experience travelled back with him from Boston. He had seen the value of OUTbio, a network for LGBTQ professionals in the biotech industry. In the United Kingdom he became a founding member of OUTbio UK, the organisation’s first international affiliate. Its purpose includes mentorship, mutual support, professional connections and friendship.
The distinction between a contact and a community matters here. An introduction can help close a transaction. A network can also give someone colleagues beyond the boundaries of a small employer. OUTbio UK creates a setting for people who may otherwise have few opportunities to meet peers with shared experiences.
Funnell remains listed as a director of the group. His aim, expressed in its team biography, is to help create the kind of supportive environment he encountered in Boston. It is another instance of noticing a working arrangement in one place and helping establish it somewhere else, with people at its centre.
The next table is already forming
The company-building continued after Ascend’s launch. In 2025, Elevara emerged with operational support and funding from Monograph, with Funnell named to its board. Ouro Medicines, another Monograph-founded business, also launched that year. The firm’s colleagues and outside partners recur across these projects, although each company has its own team and assignment.
Ouro supplied a substantial transaction in 2026. Gilead and Lakefront completed its acquisition on 4 June, with $1.675 billion in upfront consideration and up to $500 million in contingent milestone payments. The companies agreed to split those amounts equally. The potential total approaches $2.2 billion, with the distinction between cash paid and conditional payments doing real work.
Funnell’s own account of Ouro’s beginnings returned to people and a journey: Jaideep Dudani’s insight, a trip to Chengdu to meet Keymed Biosciences, and colleagues who helped bring the business forward. The thanks were distributed across founders, investors and the operating team. His account gave Charlie Zhou, a Monograph colleague, particular credit for staying with the project from its beginning.
A further appointment followed in June 2026, when Funnell became a director of RQ Biotechnology Holdings. The dates give his career a different rhythm from the familiar ascent through a single organisation. Businesses launch, responsibilities change, transactions finish, and another team begins its work. The continuity lies in participation across those stages.
Return to the empty chair. There is a modest pleasure in an investment partner finding himself responsible for the team photograph. Funnell’s explanation needed no grand theory of leadership. Somebody had to step out of the frame and take the picture. His career makes that small change of position feel entirely at home.